CoChat

Comparison of the Metabolic Effects of Raloxifene and Oral Estrogen in Postmenopausal and Growth Hormone-Deficient Women

Gibney, James, Johannsson, Gudmundur, Leung, Kin-Chuen, Ho, Ken K. Y. · 2005 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

CONTEXT: The endocrine and metabolic functions of the liver are affected by estrogen. Oral estrogen reduces IGF-I and suppresses fat oxidation despite augmenting GH secretion. The aim of this study was to determine whether selective estrogen receptor modulators display similar effects and whether these effects are magnified in GH-deficient (GHD) women because of the loss of GH feedback. DESIGN: This was an open-label, randomized, two-period, crossover study comparing treatment (raloxifene vs. estradiol) and group (normal vs. GHD). SETTING: The setting of this study was a clinical research unit. PARTICIPANTS: Twelve postmenopausal women and 12 women with hypopituitarism participated in this study. INTERVENTION: Two 4-wk treatments with 17beta-estradiol (E2; 2 mg, followed by 4 mg) or raloxifene (60 mg, followed by 120 mg) were given, crossing over to the alternate treatment after a 4-wk washout period. OUTCOME MEASURES: Endocrine [GH, IGF-I, IGF-binding protein-3 (IGFBP-3), GH-binding protein, and SHBG] and metabolic (fat oxidation) end points were used as outcome measures. RESULTS: E2 reduced serum IGF-I levels in a dose-dependent manner in both groups, with effects greater (P < 0.05) than raloxifene. Raloxifene reduced IGF-I levels in the GHD group (P < 0.001), but not in the postmenopausal group. E2 reduced (P < 0.05), and raloxifene increased (P < 0.05), IGFBP-3 levels in both groups. E2, but not raloxifene, increased GH (P < 0.05) in postmenopausal women. The effects of E2 and raloxifene on IGF-I, IGFBP-3, IGF-I/IGFBP-3 molar ratio, GH-binding protein, and SHBG were significantly different (P < 0.05). E2 and raloxifene reduced (P < 0.05) fat oxidation equally in GHD, whereas the decrease in postmenopausal women was not significant. CONCLUSION: E2 and raloxifene exert different hepatic endocrine, but not lipid oxidative, effects. The greater effects seen in GHD women may be explained by the loss of endogenous GH feedback.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2005-0173

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

See all 40

Metadata

Authors
Gibney, J., Johannsson, G., Leung, K.-C., & Ho, K. K. Y.
Affiliations
  • Garvan Institute of Medical Research (AU)
  • St Vincent's Hospital Sydney (AU)
Corresponding author
Ho, Ken K. Y.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2005-07
Volume
90
Issue
7
Pages
3897-3903
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2160962105
Cited by
40
References
42
Citations by year
2023: 1 · 2021: 1 · 2018: 1 · 2017: 4 · 2016: 2 · 2015: 2 · 2013: 3 · 2012: 4
FWCI
1.46
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Medical Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
raloxifene, estradiol, selective estrogen receptor modulators, growth hormone deficiency, hypopituitarism, postmenopausal women, insulin-like growth factor I, IGFBP-3, fat oxidation, hepatic metabolism, liver function, sex hormone-binding globulin, GH-binding protein
MeSH terms
Adolescent, Adult, Energy Metabolism, Estradiol, Female, Humans, Insulin-Like Growth Factor I, Middle Aged, Oxidation-Reduction, Sex Hormone-Binding Globulin, Postmenopause, Cross-Over Studies, Insulin-Like Growth Factor Binding Protein 3, Human Growth Hormone, Raloxifene Hydrochloride, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of the Metabolic Effects of Raloxifene and Oral Estrogen in Postmenopausal and Growth Hormone-Deficient Women. https://app.cochat.ai/papers/10.1210/jc.2005-0173
The paper
Gibney, J., Johannsson, G., Leung, K.-C., & Ho, K. K. Y. (2005). Comparison of the Metabolic Effects of Raloxifene and Oral Estrogen in Postmenopausal and Growth Hormone-Deficient Women. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-0173

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.